<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>LENS Verification Report &mdash; clinical_signal_03</title>
<style>
  * { margin: 0; padding: 0; box-sizing: border-box; }
  body { font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, sans-serif;
         max-width: 960px; margin: 2rem auto; padding: 0 1rem; color: #1e293b; background: #f8fafc; }
  h1 { font-size: 1.6rem; margin-bottom: .5rem; }
  h2 { font-size: 1.2rem; margin: 1.5rem 0 .75rem; border-bottom: 2px solid #e2e8f0; padding-bottom: .25rem; }
  .meta { color: #64748b; font-size: .9rem; margin-bottom: 1.5rem; }
  .meta span { display: inline-block; margin-right: 1.5rem; margin-bottom: .25rem; }
  table { width: 100%; border-collapse: collapse; margin-bottom: 1.5rem; }
  th, td { text-align: left; padding: .5rem .75rem; border-bottom: 1px solid #e2e8f0; font-size: .9rem; }
  th { background: #f1f5f9; font-weight: 600; font-size: .85rem; text-transform: uppercase; color: #475569; }
  .bar-bg { width: 100%; height: 1rem; background: #e2e8f0; border-radius: .25rem; overflow: hidden; }
  .bar { height: 100%; border-radius: .25rem; }
  .badge { display: inline-block; padding: .15rem .5rem; border-radius: .25rem; font-size: .8rem; font-weight: 600; color: white; }
  .badge-pass { background: #22c55e; }
  .badge-fail { background: #ef4444; }
  .badge-na { background: #94a3b8; }
  .check { color: #22c55e; font-weight: bold; }
  .cross { color: #ef4444; font-weight: bold; }
  details { margin-bottom: .5rem; }
  summary { cursor: pointer; font-weight: 600; padding: .4rem 0; }
  details ul { margin: .5rem 0 .5rem 1.5rem; }
  .timeline { display: flex; margin-bottom: 1.5rem; border-radius: .25rem; overflow: hidden; }
  .phase-bar { height: 2rem; display: flex; align-items: center; justify-content: center;
                font-size: .75rem; font-weight: 600; color: white; min-width: 40px; }
  .density-none { background: #94a3b8; }
  .density-low { background: #3b82f6; }
  .density-medium { background: #f97316; }
  .density-high { background: #ef4444; }
  .not-run { color: #94a3b8; font-style: italic; }
  .answer-text { background: #f1f5f9; padding: .5rem; border-radius: .25rem; font-size: .85rem;
                  white-space: pre-wrap; word-break: break-word; max-height: 200px; overflow-y: auto; }
</style>
</head>
<body>
<h1>LENS Verification Report</h1>
<div class="meta">
  <span><strong>Scope:</strong> clinical_signal_03</span>
  <span><strong>Domain:</strong> clinical_notes</span>
  <span><strong>Episodes:</strong> 30</span>
  <span><strong>Questions:</strong> 4</span>
  <span><strong>Model:</strong> </span>
  <span><strong>Verified:</strong> 2026-02-17T03:35:26.021389+00:00</span>
  <span><strong>Generated:</strong> 2026-02-17T03:35:26.021203+00:00</span>
</div>
<h2>Episode Timeline</h2>
<div class="timeline"><div class="phase-bar density-none" style="width:26.7%" title="baseline: eps 1-8, none">baseline</div><div class="phase-bar density-low" style="width:23.3%" title="early_signal: eps 9-15, low">early_signal</div><div class="phase-bar density-medium" style="width:10.0%" title="red_herring: eps 14-16, medium">red_herring</div><div class="phase-bar density-high" style="width:23.3%" title="escalation: eps 16-22, high">escalation</div><div class="phase-bar density-high" style="width:26.7%" title="root_cause: eps 23-30, high">root_cause</div></div>
<h2>Key Fact Coverage</h2>
<table>
  <thead><tr><th>Fact ID</th><th>Fact</th><th>Found</th><th>Missing</th><th>Hit Rate</th></tr></thead>
  <tbody>
        <tr>
          <td>statin_subgroup_alt</td>
          <td>progressive transaminase creep in co-medicated cohort trending toward action threshold</td>
          <td>1/4</td>
          <td>clinical_signal_03_ep_010, clinical_signal_03_ep_017, clinical_signal_03_ep_025</td>
          <td><div class="bar-bg"><div class="bar" style="width:25%;background:#ef4444"></div></div></td>
        </tr>
        <tr>
          <td>cross_site_pattern</td>
          <td>hepatic signal present across multiple sites not just Site 07</td>
          <td>3/3</td>
          <td>-</td>
          <td><div class="bar-bg"><div class="bar" style="width:100%;background:#22c55e"></div></div></td>
        </tr>
        <tr>
          <td>ddi_mechanism</td>
          <td>drug-drug interaction with statin via CYP3A4 inhibition</td>
          <td>3/3</td>
          <td>-</td>
          <td><div class="bar-bg"><div class="bar" style="width:100%;background:#22c55e"></div></div></td>
        </tr>
        <tr>
          <td>site07_red_herring</td>
          <td>Site 07 lab equipment issue is not the cause of ALT elevations</td>
          <td>2/2</td>
          <td>-</td>
          <td><div class="bar-bg"><div class="bar" style="width:100%;background:#22c55e"></div></div></td>
        </tr>
  </tbody>
</table>
<h2>Contamination Check <span class="badge badge-pass">PASS</span></h2>
<table>
  <thead><tr><th>Question</th><th>Status</th><th>Max Single-Episode Coverage</th><th>Worst Episode</th></tr></thead>
  <tbody>
        <tr>
          <td>cs03_q01_longitudinal</td>
          <td><span class="badge badge-pass">PASS</span></td>
          <td>
            <div class="bar-bg"><div class="bar" style="width:0%;background:#22c55e"></div></div>
            0.0%
          </td>
          <td>None</td>
        </tr>
        <tr><td colspan="4">
        <details>
          <summary>Per-episode scores (12 episodes)</summary>
          <ul><li><strong>clinical_signal_03_ep_001</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_002</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_003</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_004</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_005</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_006</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_007</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_008</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_009</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_010</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_011</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_012</strong>: 0.0%</li></ul>
        </details></td></tr>
        <tr>
          <td>cs03_q03_longitudinal</td>
          <td><span class="badge badge-pass">PASS</span></td>
          <td>
            <div class="bar-bg"><div class="bar" style="width:0%;background:#22c55e"></div></div>
            0.0%
          </td>
          <td>None</td>
        </tr>
        <tr><td colspan="4">
        <details>
          <summary>Per-episode scores (25 episodes)</summary>
          <ul><li><strong>clinical_signal_03_ep_001</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_002</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_003</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_004</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_005</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_006</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_007</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_008</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_009</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_010</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_011</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_012</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_013</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_014</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_015</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_016</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_017</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_018</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_019</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_020</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_021</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_022</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_023</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_024</strong>: 0.0%</li><li><strong>clinical_signal_03_ep_025</strong>: 0.0%</li></ul>
        </details></td></tr>
  </tbody>
</table>

<h2>Naive Baseline</h2>
<div class="meta"><span><strong>longitudinal:</strong> 0.0%</span> <span><strong>null_hypothesis:</strong> 100.0%</span> <span><strong>action_recommendation:</strong> 0.0%</span> </div>
<table>
  <thead><tr><th>Question</th><th>Type</th><th>Fact Coverage</th></tr></thead>
  <tbody>
        <tr>
          <td>cs03_q01_longitudinal</td>
          <td>longitudinal</td>
          <td>
            <div class="bar-bg"><div class="bar" style="width:0%;background:#ef4444"></div></div>
            0.0%
          </td>
        </tr>
        <tr><td colspan="3">
          <ul><li><span class="cross">&#10007;</span> progressive transaminase creep in co-medicated cohort trending toward action threshold (10%)</li></ul>
          <details><summary>Full answer</summary><div class="answer-text">Based on the trial data provided, several observations can be made regarding the safety signals in the lab panels across the different records:

1. **Liver Function Tests (LFTs)**:
   - The mean ALT (Alanine Aminotransferase) levels in the statin subgroup have shown variability, with some records indicating values approaching or exceeding the upper limit of normal (ULN). For instance, in Record 11, the mean ALT was reported at 47.6 U/L, which is above the typical upper limit of around 40 U/L for most laboratories. This could indicate potential liver function concerns in the statin group.
   - Similarly, in Record 12, the mean ALT was reported at 47.2 U/L, again suggesting elevated liver enzyme levels.

2. **Renal Function Tests**:
   - The serum creatinine levels across various records show some fluctuations, particularly in the higher dose groups. For example, in Record 11, the mean serum creatinine was reported at 1.09 mg/dL, which is on the higher side of normal. In Record 12, it was reported at 1.07 mg/dL. Elevated creatinine levels can indicate renal impairment, which is a concern, especially in the context of the high dose groups.
   - The UACR (Urine Albumin-to-Creatinine Ratio) values also show variability, with some records indicating higher levels, which could suggest renal stress or damage.

3. **Adverse Events**:
   - There are multiple reports of adverse events related to fatigue, malaise, and gastrointestinal issues (e.g., nausea, constipation) across various records. While these may not directly correlate with lab panel results, they can indicate a broader safety signal that warrants further investigation.
   - Specific adverse events such as &quot;transaminase measurement out of range&quot; (Record 11) and &quot;hyperkalemia&quot; (Record 12) suggest that there are instances where lab results have raised concerns that need to be monitored closely.

4. **Trends Over Time**:
   - As the trial progresses, there appears to be a trend of increasing mean values for certain biomarkers, particularly in the high dose groups. This could indicate a cumulative effect of the treatment that may lead to safety concerns if not addressed.

5. **Overall Safety Signals**:
   - The combination of elevated liver enzymes, fluctuating renal function markers, and the occurrence of adverse events suggests that there may be emerging safety signals that need to be closely monitored. It is essential to continue evaluating these lab panels and correlate them with clinical outcomes to determine the significance of these findings.

In conclusion, while there are no definitive safety signals that indicate a crisis, the data suggests that there are emerging concerns, particularly related to liver and renal function, that should be monitored closely as the trial continues. Regular safety assessments and possibly dose adjustments may be warranted based on these findings.</div></details>
        </td></tr>
        <tr>
          <td>cs03_q02_null</td>
          <td>null_hypothesis</td>
          <td>
            <div class="bar-bg"><div class="bar" style="width:100%;background:#22c55e"></div></div>
            100.0%
          </td>
        </tr>
        <tr><td colspan="3">
          
          <details><summary>Full answer</summary><div class="answer-text">In the Week 6 summary (Record 6, dated 2024-04-08), the enrollment count at Site 03 was 18.</div></details>
        </td></tr>
        <tr>
          <td>cs03_q03_longitudinal</td>
          <td>longitudinal</td>
          <td>
            <div class="bar-bg"><div class="bar" style="width:0%;background:#ef4444"></div></div>
            0.0%
          </td>
        </tr>
        <tr><td colspan="3">
          <ul><li><span class="cross">&#10007;</span> progressive transaminase creep in co-medicated cohort trending toward action threshold (20%)</li><li><span class="cross">&#10007;</span> hepatic signal present across multiple sites not just Site 07 (10%)</li><li><span class="cross">&#10007;</span> drug-drug interaction with statin via CYP3A4 inhibition (29%)</li><li><span class="cross">&#10007;</span> Site 07 lab equipment issue is not the cause of ALT elevations (33%)</li></ul>
          <details><summary>Full answer</summary><div class="answer-text">The hepatic adverse events observed in this trial appear to be primarily driven by the administration of statins, as indicated by the data collected throughout the study. Here are the key points that support this conclusion:

1. **Increased Liver Enzymes**: The records consistently show elevated levels of liver enzymes (ALT and AST) in the statin subgroup. For instance, in the most recent records, the mean ALT levels reached as high as 133.5 U/L, with some reports indicating values exceeding 2-3 times the upper limit of normal (ULN). This elevation is a common indicator of liver stress or damage.

2. **Adverse Events Related to Hepatic Function**: Several adverse events specifically related to hepatic function have been reported, including cases of hepatocellular injury, jaundice, and transaminase measurements out of range. The severity of these events has ranged from Grade 1 to Grade 3, indicating a significant concern for liver health among participants receiving statins.

3. **Correlation with Statin Administration**: The adverse events are predominantly reported in subjects receiving statin treatment, suggesting a direct correlation between statin use and the occurrence of hepatic adverse events. The records indicate that the majority of the hepatic adverse events were classified as possibly or probably related to the statin treatment.

4. **Dose-Dependent Response**: The data also suggest a dose-dependent relationship, where higher doses of statins correlate with increased liver enzyme levels and a higher incidence of hepatic adverse events. This is consistent with known pharmacological effects of statins, which can lead to liver enzyme elevation.

5. **Monitoring and Reporting**: The trial has been actively monitoring liver function tests and reporting any abnormalities. The consistent documentation of elevated liver enzymes and related adverse events indicates that the study is aware of the potential risks associated with statin therapy.

In summary, the hepatic adverse events in this trial are likely driven by the administration of statins, as evidenced by elevated liver enzyme levels, the nature of reported adverse events, and the correlation with statin treatment. Continuous monitoring and potential adjustments to the treatment protocol may be necessary to mitigate these risks.</div></details>
        </td></tr>
        <tr>
          <td>cs03_q04_action</td>
          <td>action_recommendation</td>
          <td>
            <div class="bar-bg"><div class="bar" style="width:0%;background:#ef4444"></div></div>
            0.0%
          </td>
        </tr>
        <tr><td colspan="3">
          <ul><li><span class="cross">&#10007;</span> drug-drug interaction with statin via CYP3A4 inhibition (43%)</li><li><span class="cross">&#10007;</span> progressive transaminase creep in co-medicated cohort trending toward action threshold (10%)</li></ul>
          <details><summary>Full answer</summary><div class="answer-text">Based on the longitudinal dataset provided, the following protocol amendments should be recommended by the Data Safety Monitoring Board (DSMB):

1. **Exclusion of Statin Co-Administration**: Given the consistent reports of elevated hepatic enzymes (ALT and AST) in the statin subgroup, particularly with values reaching 3-4 times the upper limit of normal (ULN) and the identification of Hy's Law cases, the DSMB should recommend excluding subjects on statins from the study. This amendment is crucial to ensure participant safety and to mitigate the risk of serious adverse events related to liver function.

2. **Increased Monitoring Frequency**: The DSMB should recommend increasing the frequency of hepatic monitoring for participants in the statin subgroup, especially those transitioning off statins. This includes more frequent liver function tests (LFTs) to closely monitor any changes in liver enzymes and to ensure timely intervention if necessary.

3. **Enhanced Adverse Event Reporting**: Given the rising number of adverse events related to hepatocellular injury and jaundice, the DSMB should recommend enhanced training for site staff on the identification and reporting of adverse events. This includes clear guidelines on what constitutes a serious adverse event (SAE) and the importance of timely reporting to ensure participant safety.

4. **Adjustment of Inclusion Criteria**: The DSMB may consider recommending adjustments to the inclusion criteria to ensure that participants with pre-existing liver conditions or those taking medications known to interact with the study drug (such as CYP3A4 substrates) are excluded from the study. This will help reduce the risk of adverse events and improve the overall safety profile of the study.

5. **Protocol for Managing Elevated Liver Enzymes**: The DSMB should recommend the development of a clear protocol for managing participants who exhibit elevated liver enzymes during the study. This protocol should outline the steps to be taken, including potential dose adjustments, additional monitoring, and criteria for withdrawal from the study.

6. **Regular Review of Safety Data**: The DSMB should recommend a more frequent review of safety data, particularly focusing on hepatic function and adverse events related to liver injury. This could involve bi-weekly or monthly reviews instead of the current schedule to ensure that any emerging safety signals are addressed promptly.

7. **Patient Education**: The DSMB should recommend implementing a patient education program that informs participants about the potential risks associated with the study drug, particularly regarding liver health. This could include information on recognizing symptoms of liver dysfunction and the importance of reporting any unusual symptoms.

By implementing these amendments, the DSMB can enhance participant safety, ensure compliance with ethical standards, and improve the integrity of the study's findings.</div></details>
        </td></tr>
  </tbody>
</table>
</body>
</html>
